Web-based Exercise for South Asian People With Type 2 Diabetes
Web-based Exercise Intervention for South Asian People With Type 2 Diabetes: a Randomised Controlled Trial
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
A mixed method approach involving both qualitative and quantitative methods will be used.
The quantitative component will consist of a single blind, randomised controlled trial (RCT), which will explore the effects of the intervention on glycaemic control (blood sugar levels) and other secondary outcomes.
The qualitative component will consist of face to face interviews to explore the views of participants regarding acceptability and barriers affecting adherence to this intervention.
Potential participants will be informed about the study at hospital diabetes clinics, community health organisations, support groups, places of worship and General Practitioner (GP) surgeries. Recruitment is estimated to last for 9 months. Potential participants will be sent a participant information sheet (PIS) in either English or Urdu, depending on their preference. Those wishing to take part will meet the researcher at a convenient location, for eligibility screening and consent. If necessary, translation services can be arranged for those with limited English throughout the study.
Following baseline assessment, participants will be randomised to either the intervention or control group. Participants in the control group will be asked to continue their usual care and day to day physical activity routine. In addition, they will be given general information about diabetes management. Participants who wish to use the website for exercise will be provided with access at the end of all assessments.
Participants assigned to the intervention group will be asked to perform a personalised exercise programme, undertaken three times a week (with no more than two rest days between sessions) for 12 weeks. Participants will meet the researcher face to face immediately after randomisation. During this meeting, a brief physical assessment will be undertaken and exercise goals will be discussed and agreed with participants. The researcher will then design a personalised exercise programme for each participant using the resources available on the web-based exercise website. The exercise programme prescription and progression will be in line with American Diabetes Association (ADA) and American College of Sports Medicine (ACSM) guidelines (Colberg et al. 2016). The website (www.webbasedphysio.com) will be used to deliver the intervention. This website has been modified, in collaboration with South Asians, to be culturally suitable for people of South Asian backgrounds in terms of content and language (Albalawi et al, under review). The researcher will contact participants every two weeks via telephone to encourage use of the website, ask about progress, and to deal with any technical issues that they might face while using the website. Participants will be advised to contact the researcher to request a change in their programme or if a problem arises. The researcher will make changes remotely and participants will be informed of any changes by phone or email. Participants will be asked to meet the researcher face to face to discuss progression and goals at week 6 (midway). Regardless of groups allocation, all participants will be assessed three times by a blind assessor at baseline (week=0) , after the end of the intervention (week=12) and 8 weeks after the end of the intervention (week=20).
Assessment of outcome measures will take place at convenient locations and each visit should take no more than 90 minutes. Travel expenses will be provided.
All participants will be informed that they are free to withdraw from the study at any time without being obliged to give notice or provide any explanation. Any data collected before their withdrawal will be considered in the analysis.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Glasgow, Reino Unido
- NHS Greater Glasgow and Clyde
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- define themselves as South Asians
- BMI 21 - 29.9 kg/m2
- diagnosed with Type 2 Diabetes Mellitus (T2DM) by a physician more than 6 months previously
- access to a personal computer/tablet, smart phone or smart television with an email address and Internet connection
- able to understand English or Urdu
Exclusion Criteria:
- type 1 diabetes
- any medical conditions that would affect adherence or contraindicate exercise including severe peripheral neuropathy, severe autonomic neuropathy, severe physical limitations, heart disease, pre-proliferative or proliferative retinopathy, uncontrolled hypertension (>180/ 100mmHg), or coronary artery disease.
- people using insulin if they do not have a self-monitoring glucose device or are unable to use such devices.
- engaging in exercise training of 150 minutes a week or more
- participating in other interventional studies aiming to improve glycaemic control
- unwilling to be randomised
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Sem intervenção: Grupo de controle
Cuidados usuais
|
|
|
Experimental: Web-based exercise programme
Personalised exercise programme, undertaken three times a week (with no more than two rest days between sessions) for 12 weeks
|
Aerobic, resistance and balance exercises
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Glycaemic control
Prazo: Baseline to 12 weeks
|
Change in HbA1c
|
Baseline to 12 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Blood lipid profile (cholesterol)
Prazo: Baseline to 12 weeks
|
Change in total cholesterol level
|
Baseline to 12 weeks
|
|
Blood lipid profile (cholesterol)
Prazo: 12 weeks to 20 weeks
|
Change in total cholesterol level
|
12 weeks to 20 weeks
|
|
Blood lipid profile (high density lipoproteins)
Prazo: Baseline to 12 weeks
|
Change in high density lipoprotein (HDL) level
|
Baseline to 12 weeks
|
|
Blood lipid profile (high density lipoproteins)
Prazo: 12 weeks to 20 weeks
|
Change in high density lipoprotein (HDL) level
|
12 weeks to 20 weeks
|
|
Blood lipid profile (low-density lipoproteins)
Prazo: Baseline to 12 weeks
|
Change in low density lipoprotein (LDL) level
|
Baseline to 12 weeks
|
|
Blood lipid profile (low-density lipoproteins)
Prazo: 12 weeks to 20 weeks
|
Change in low density lipoprotein (LDL) level
|
12 weeks to 20 weeks
|
|
Blood lipid profile (triglyceride)
Prazo: Baseline to 12 weeks
|
Change in triglyceride level
|
Baseline to 12 weeks
|
|
Blood lipid profile (triglyceride)
Prazo: 12 weeks to 20 weeks
|
Change in triglyceride level
|
12 weeks to 20 weeks
|
|
Blood pressure
Prazo: Baseline to 12 weeks
|
Change in blood pressure result
|
Baseline to 12 weeks
|
|
Blood pressure
Prazo: 12 weeks to 20 weeks
|
Change in blood pressure result
|
12 weeks to 20 weeks
|
|
Body mass index (BMI)
Prazo: Baseline to 12 weeks
|
Change in BMI
|
Baseline to 12 weeks
|
|
Body mass index (BMI)
Prazo: 12 weeks to 20 weeks
|
Change in BMI
|
12 weeks to 20 weeks
|
|
Waist circumference
Prazo: Baseline to 12 weeks
|
Change in waist circumference
|
Baseline to 12 weeks
|
|
Waist circumference
Prazo: 12 weeks to 20 weeks
|
Change in waist circumference
|
12 weeks to 20 weeks
|
|
Ten metre walking test (10MWT)
Prazo: Baseline to 12 weeks
|
Change in 10 MWT result
|
Baseline to 12 weeks
|
|
Ten metre walking test (10MWT)
Prazo: 12 weeks to 20 weeks
|
Change in 10 MWT result
|
12 weeks to 20 weeks
|
|
Timed Up and Go test
Prazo: Baseline to 12 weeks
|
Change in Timed Up and Go test result
|
Baseline to 12 weeks
|
|
Timed Up and Go test
Prazo: 12 weeks to 20 weeks
|
Change in Timed Up and Go test result
|
12 weeks to 20 weeks
|
|
Muscle power
Prazo: Baseline to 12 weeks
|
Change in hand grip dynamometer score
|
Baseline to 12 weeks
|
|
Muscle power
Prazo: 12 weeks to 20 weeks
|
Change in hand grip dynamometer score
|
12 weeks to 20 weeks
|
|
Quality of Life - WHO-QOL BREF score
Prazo: Baseline to 12 weeks
|
Change in World Health Organisation Quality of Life (WHO-QOL BREF) score
|
Baseline to 12 weeks
|
|
Quality of Life - WHO-QOL BREF score
Prazo: 12 weeks to 20 weeks
|
Change in World Health Organisation Quality of Life (WHO-QOL BREF) score
|
12 weeks to 20 weeks
|
|
Adherence - exercise diary completion
Prazo: 12 weeks
|
Number of times exercise diary completed
|
12 weeks
|
|
Dietary intake
Prazo: Baseline to 12 weeks
|
Change in Food Frequency Questionnaire score
|
Baseline to 12 weeks
|
|
Dietary intake
Prazo: 12 weeks to 20 weeks
|
Change in Food Frequency Questionnaire score
|
12 weeks to 20 weeks
|
|
Change in Medication
Prazo: Baseline to 12 weeks
|
Change in medication
|
Baseline to 12 weeks
|
|
Change in Medication
Prazo: 12 weeks to 20 weeks
|
Change in medication
|
12 weeks to 20 weeks
|
|
Glycaemic control
Prazo: 12 weeks to 20 weeks
|
Change in HbA1c
|
12 weeks to 20 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Diretor de estudo: Lorna Paul, PhD, Glasgow Caledonian University
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- GN17DI329
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .